Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Avista Public Acquisition Corp II Cl A (NQ: AHPA ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Nov 1, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 5.200 (10) Ask (Size) 6.280 (1) Prev. Close 6.125 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday October 31, 2022 Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. Via Benzinga OmniAb Business Combination Approved by APAC Shareholders October 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Performance More News Read More Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session October 28, 2022 Via Benzinga Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients August 25, 2022 Via Benzinga Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma August 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Second Quarter 2022 Financial Results August 08, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports First Quarter 2022 Financial Results May 04, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL March 24, 2022 Via Benzinga Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger March 24, 2022 Via Benzinga Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II March 23, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.